Patents Examined by Sahar Javanmard
  • Patent number: 11684594
    Abstract: The technology described herein is directed to ionic liquids for using the treatment or prevention of fungal infections.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: June 27, 2023
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Samir Mitragotri, Eden E. L. Tanner
  • Patent number: 11679087
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Angelman syndrome (AS). CBD has been shown to be particularly effective in improving anxiety in rodent models of AS. The CBD is preferably substantially pure. It may take the form of a highly purified extract of Cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBD is synthetically produced. Alternatively, the CBD may be used as a botanical drug substance (BDS) from a Cannabis plant in which CBD is the predominant cannabinoid. The CBD may also be present in combination with other cannabinoids and non-cannabinoid components such as terpenes. In use the CBD may be used concomitantly with one or more other medicaments. Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more medicaments or the combination may be provided in a single dosage form.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: June 20, 2023
    Inventors: Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Livio Luongo
  • Patent number: 11666586
    Abstract: Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of acne vulgaris. The compositions include succinic acid and an API selected from the group consisting of salicylic acid, azelaic acid, picolinic acid, benzoyl peroxide, antibiotic, retinoid and combinations thereof in a pharmaceutically acceptable preparation. The compositions that include the combination of succinic acid and another API produce improved efficacy in treating acne vulgaris.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: June 6, 2023
    Assignee: Dermala, Inc.
    Inventors: Lada Rasochova, Michelle Kem
  • Patent number: 11654170
    Abstract: Novel plant products customized to provide a desired, consistent and stable Entourage of Interest (EOI) and processes for making and using the same are provided.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: May 23, 2023
    Assignee: Perfect Herbal Blends, Inc.
    Inventor: Michael Dane Backes
  • Patent number: 11654146
    Abstract: Disclosed herein are compounds, compositions, and methods for treating infections by bacteria and for killing bacteria. In particular, the disclosed compounds, compositions, and methods are useful for treating infections by bacteria and for killing persister bacteria that survive antibiotic treatment and then reconstitute infections.
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: May 23, 2023
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Thomas Keith Wood, Sooyeon Song
  • Patent number: 11642333
    Abstract: The present invention relates to a liquid, propellant-free pharmaceutical preparation and a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) an active substance selected from umeclidinium bromide and vilanterol trifenatate and combinations thereof; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; and (d) a pharmacologically acceptable preservative, and optionally includes a pharmacologically acceptable stabilizer, a pharmacologically acceptable co-solvent, or other pharmacologically acceptable additives.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: May 9, 2023
    Assignee: ANOVENT PHARMACEUTICAL (U.S.), LLC
    Inventors: Cai Gu Huang, Ying Ai Xu, Yue Zhao, Hui Yuan
  • Patent number: 11638733
    Abstract: Novel plant products customized to provide a desired, consistent and stable Entourage of Interest (EOI) and processes for making and using the same are provided.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: May 2, 2023
    Assignee: Perfect Herbal Blends, Inc.
    Inventor: Michael Dane Backes
  • Patent number: 11633373
    Abstract: The present invention relates to the use of guanidinoacetic acid and a method of treating caudophagia in pigs.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: April 25, 2023
    Assignee: Alzchem Trostberg GmbH
    Inventor: J├╝rgen Sans
  • Patent number: 11629118
    Abstract: Formulations containing pharmaceutically active compounds with improved stability.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: April 18, 2023
    Assignee: INSPIRNA, INC.
    Inventors: Eduardo Martinez, Peter Rix, Eric Gruff
  • Patent number: 11612583
    Abstract: The present invention relates to the discovery that Forskolin can be used to treat Parkinson's disease (PD) in subjects in need thereof. In certain embodiments, the invention provides a method of treating PD, wherein a therapeutically effective amount of Forskolin is administered to a subject via intranasal or intrapulmonary routes. In other embodiments, the subject is further administered a therapeutically effective amount of Noopept. In yet other embodiments, the method reverses damage to the subject's brain caused by PD and promotes growth of new neurons.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: March 28, 2023
    Assignee: Nevada Research & Innovation Corporation
    Inventors: Raul Y. Dagda, Ruben K. Dagda
  • Patent number: 11590117
    Abstract: Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: February 28, 2023
    Assignee: Celgene Corporation
    Inventors: Soraya Carrancio, Paul Hollenbach, Antonia Lopez-Girona, Kyle MacBeth, Michael Pourdehnad, Irit Rappley, Gang Lu
  • Patent number: 11590149
    Abstract: Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of acne vulgaris. The compositions include succinic acid and an API selected from the group consisting of salicylic acid, azelaic acid, picolinic acid, benzoyl peroxide, antibiotic, retinoid and combinations thereof in a pharmaceutically acceptable preparation. The compositions that include the combination of succinic acid and another API produce improved efficacy in treating acne vulgaris.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: February 28, 2023
    Assignee: Dermala, Inc.
    Inventors: Lada Rasochova, Michelle Kem
  • Patent number: 11584717
    Abstract: The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 21, 2023
    Assignee: YALE UNIVERSITY
    Inventors: William L. Jorgensen, Richard J. Bucala
  • Patent number: 11583528
    Abstract: The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and/or tumors more generally. Therapeutic and/or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: February 21, 2023
    Inventors: Lois Smith, Jean-Sebastien Joyal
  • Patent number: 11564927
    Abstract: This invention relates to methods comprising administering a FAK inhibitor and an immunotherapeutic agent such as anti-PD-1 or anti-PD-L1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: January 31, 2023
    Assignee: Verastem, Inc.
    Inventors: Jonathan A. Pachter, Jennifer E. Ring, David T. Weaver, Yan Wang
  • Patent number: 11564934
    Abstract: The invention relates to pharmaceutical compositions comprising a corticosteroid and an antioxidant. The invention further relates to methods of treating, preventing, or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract comprising administering the pharmaceutical compositions comprising a corticosteroid and an antioxidant.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: January 31, 2023
    Assignee: ViroPharma Biologies LLC
    Inventor: Ramalingeswar Kasina
  • Patent number: 11566016
    Abstract: The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38? MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.
    Type: Grant
    Filed: September 16, 2021
    Date of Patent: January 31, 2023
    Assignees: The Trustees of Columbia University in the City of New York, Northwestern University
    Inventors: Ottavio Arancio, Daniel Martin Watterson, Jeffrey Claude Pelletier, Saktimayee Mitra Roy
  • Patent number: 11559532
    Abstract: The invention provides a composition and method for treating prostate disorders. The composition can be formulated to provide a saw palmetto oil having about 3% w/w ?-sitosterol.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: January 24, 2023
    Assignee: Vidya Herbs, Inc.
    Inventor: Kodimule Shyam Prasad
  • Patent number: 11541057
    Abstract: Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: January 3, 2023
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Patent number: 11542264
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: January 3, 2023
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser